Cunninghamella spp., in the class Zygomycete and order Mucorales, are unusual opportunistic pathogens that have been identified with increased frequency in immunocompromised patients. Infections with this group of organisms have been seen most frequently in patients with hematologic malignancy. We describe an allogeneic bone marrow recipient who developed fungal pneumonitis and disseminated fungal dermatitis caused by Cunninghamella spp. To our knowledge, this is the first reported case of Cunninghamella infection in a BMT recipient. The case highlights the mortality associated with opportunistic infections in immunocompromised patients and confirms the risk factors associated with non-candida fungal infections after bone marrow transplantation. Bone Marrow Transplantation (2000) 25, 1213-1216.
has been identified as the etiologic agent in 26 cases of zygomycosis reported in the literature. We report the case of a 46-year-old woman who developed fungal pneumonitis and disseminated fungal dermatitis caused by Cunninghamella spp. 8 months after undergoing allogeneic bone marrow transplantation from a matched (8 of 8 HLA antigen) unrelated donor. Among uncommon fungal infections in BMT patients, mucormycosis infection has been reported most frequently. Morrison and McGlave 4 reported a series of 13 BMT patients who developed mucormycosis infection. To our knowledge, this is the first reported case of Cunninghamella infection in a BMT recipient.
Case report
A 46-year-old Caucasian female was initially diagnosed in February 1995 with chronic myelogenous leukemia (CML). She underwent a splenectomy 1 month preceding her transplant. In February 1997, she received a genotypically (HLA-A, B, DR and DQ) matched unrelated donor T celldepleted allogeneic BMT following a preparative regimen consisting of cytarabine, cyclophosphamide, solumedrol and total body irradiation while in first accelerated phase CML. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine (starting day −1). She showed evidence of hematopoietic engraftment (Ͼ500 neutrophils/ mm 3 ) on day +18. Her post-transplant course was complicated by the development of grade I GVHD of the skin (biopsy proven). She was treated with pulse corticosteroids at 1 mg/kg twice a day for 1 week followed by tapered dosage with gradual resolution of her rash. She was discharged on day +25 on oral cyclosporine and prednisone and topical corticosteroids. She also received prophylactic fluconazole 400 mg/day as antifungal prophylaxis the entire time she was on steroids. The steroids were slowly tapered over the course of the next few months. She continued on oral cyclosporine. Her outpatient course was complicated by four episodes of cytomegalovirus (CMV) antigenemia requiring either gancyclovir or foscarnet therapy and an admission in May 1997 for Klebsiella oxytoca bacteremia. Her day +100 evaluation showed complete chimerism with a normal bone marrow. On day +104, mild abnormalities in her liver function tests developed and a few days later a labial rash was noted. Both of these findings were inter- preted as consistent with GVHD. Her steroid dose was increased from 25 mg to 40 mg. Her skin rash and liver function tests improved and her steroid dose was again slowly tapered. Her day +180 evaluation showed complete chimerism with a normal bone marrow. However, molecular analysis for the presence of bcl/abl translocation was positive.
She did well until mid-September when she was admitted with a 4 day history of diarrhea, nausea, vomiting and poor oral intake. At the time of admission, she was on oral cyclosporine 60 mg and prednisone 10 mg daily. A colonoscopy was performed showing pancolitis with patchy ulcerations; biopsies revealed grade II acute GVHD. She was treated with high-dose solumedrol 1 mg/kg twice a day which was tapered to 15 mg twice a day. Her course was complicated by hemolytic uremic syndrome with subsequent acute renal failure requiring hemodialysis, recurrent CMV viremia and multi-organ bacteremia (coagulase-negative Staphylococcus and gram-negative rods). On the 16th day of hospitalization, she developed respiratory insufficiency with a chest X-ray revealing bilateral pulmonary infiltrates and a nodular retrocardiac opacity. Despite broad-spectrum antibacterial, antiviral and antifungal antibiotics, she continued to deteriorate both clinically and radiographically (chest Xrays and chest CT). Due to worsening pulmonary infiltrates, liposomal amphotericin B (5 mg/kg) was initiated due to suspicion of fungal pneumonitis. On the 19th day of hospitalization, she developed numerous erythematous skin lesions which displayed central necrosis (Figures 1 and 2) . A skin biopsy revealed angioinvasive fungal organisms with significant distortion but dichotomous branching and occasional septation. These morphologic features were interpreted as most consistent with Aspergillus spp. Cultures were not performed. The skin lesions rapidly became florid and diffusely distributed, despite continued high-dose intravenous amphotericin B. Her mental status declined and a head CT showed multiple hypodense lesions suggestive of an infectious etiology vs infarction. The patient expired on the 21st hospital day from multi-system failure corresponding to day +230 post T cell-depleted allogeneic matched unrelated bone marrow transplant.
An autopsy, limited to examination of the lungs, demonstrated fungal pneumonia with multifocal vascular occlusion containing masses of broad, pauciseptate fungal hyphae (Figure 3 
Discussion
There have been 26 reported cases of invasive Cunninghamella infection. Since Hutter's original report in 1959, 5 our patient is the only bone marrow transplant recipient with disseminated fungal infection caused by Cunninghamella. Hematologic malignancy is the most common underlying illness reported in patients with Cunninghamella infection. A variety of other underlying illnesses reported include diabetes melllitus, AIDS, solid organ transplantation and chronic anemia. The fungus has been documented as the etiologic agent of fatal pneumonia in one immunocompetent patient. 6 The present case shares many features in common with those of previously reported cases of Cunninghamella infection. Tables 1 and 2 depict characteristics of 26 patients with documented Cunninghamella infection. The patients ranged in age from 3 to 70 years. Four patients were female and 20 male. Age and gender is unknown for two cases. Pulmonary infection was the primary site in all but seven cases. Mortality was 77% with a short median survival (2-3 weeks). Antemortem recovery of the organism was obtained in 55% of the cases. Amphotericin therapy, employed in 15 of the 26 cases, resulted in an improved, but still dismal mortality of 60%. There have been two survivors with pulmonary involvement 7, 8 and four survivors with extrapulmonary disease. [9] [10] [11] [12] Survival from pulmonary infection was associated with pulmonary lobectomy or wedge resection plus long-term amphotericin B therapy. Among survivors with extrapulmonary disease, three received debridement/resection of the involved site and all received amphotericin B therapy with a total dose of at least 1 g. Our patient had initial evidence of pulmonary infection with rapid dissemination to skin and presumably the brain. However, identification of Cunninghamella was not obtained until after death. Amphotericin B therapy was initiated on the first day of radiographic evidence of pulmonary infiltrates. She had been receiving fluconazole throughout her post-transplant course. She died 5 days after pulmonary symptoms developed. This suggests that neither 
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Bone Marrow Transplantation prophylasis nor prompt intervention improves survival. Based upon the course of previous survivors, amphotericin B therapy combined with early aggressive surgical debridement/resection of involved tissues optimizes survival.
The present case offers some uncommon and unique features. Disseminated Cunninghamella infection has been documented in seven previous patients, three of whom had brain involvement. Brain involvement in our case was diagnosed based upon computed tomographic findings consisting of widespread, focal hypodense areas.
Disseminated skin lesions have not been described in other cases. However, localized skin lesions were noted in three previous patients. There was evidence of direct trauma to the knee in a 27-year-old man with AIDS. 13 Skin lesions involved the affected knee and Cunninghamella was isolated from the joint fluid. In another case, a 42-year-old man with thalassemia, transient neutropenia and hemochromatosis had Cunninghamella infection involving the submandibular gland, as well as cervical and axillary lymph nodes. 10 Skin lesions were present overlying the affected areas. In the third case, a 69-year-old man with diabetes had a leg wound infected with Cunninghamella, which was presumed to be nosocomial in origin. 9 Characteristic skin lesions have been described in other fungal infections including Candida, Aspergillus and Fusarium species. 14, 15 Our patient had disseminated erythematous/purpuric, necrotic papules, which are similar to the lesions described in Aspergillus and Fusarium infections. 14, 15 There is no consistent association of cutaneous manifestations with pulmonary disease. Skin lesions were noted 3 days after the onset of pulmonary symptoms in our patient and rapidly disseminated over the course of 1 day.
Cunninghamella occurring in immunocompromised patients classically follows a pattern of pulmonary infection and carries a high mortality rate. However, dissemination to other organs does occur. Prognosis is ominous despite therapy. These features were evident in this bone marrow transplant patient with the unique aspect of disseminated skin lesions. Risk factors associated with the development of non-candida fungal infections after bone marrow transplantation have been previously described and include: (1) allogeneic BMT, (2) age Ͼ18 years, (3) development of GVHD and (4) CMV positive serology at time of trans-plant. 1 Our patient had all of these risk factors. The development of acute GVHD is associated with high mortality from infectious complications because of the immunodeficiency associated with GVHD and the immunosuppressive therapy used to treat it. 16, 17 In summary, we describe a fatal case of Cunninghamella infection in an allogeneic bone marrow transplant recipient following treatment for gastrointestinal GVHD. This case highlights the mortality associated with opportunistic infections in immunocompromised patients, confirms the risk factors associated with non-candida fungal infections after bone marrow transplantation and establishes Cunninghamella as another etiologic agent of disseminated fungal dermatitis in this clinical setting.
